AGP Executive Report
Last update: 5 hours agoCBD/Medical Safety: The CDC reports a sharp rise in ER visits tied to cannabis hyperemesis syndrome (CHS) after a new CHS diagnosis code took effect in Oct. 2025, with CHS-related visits jumping from 3.35 to 11.26 per 10,000 ED visits and staying elevated through May 2026. Oncology Research: Lab work suggests some cannabinoids (including CBD and CBGV) may make glioblastoma cells less vulnerable to chemotherapy and radiation by shifting cell-death pathways, raising questions about “anticancer” assumptions and the need for clinical follow-up. Clinical/Patient Impact: A study on fibromyalgia patients found topical CBD can reduce localized pain, while another survey reports people with inflammatory bowel disease report better quality of life and fewer opioids after cannabis use. Policy/Access: A federal judge ruled New Jersey’s labor-peace agreement requirement for cannabis licenses is preempted by federal labor law, clearing a faster appeal path. Legal/Enforcement: Nevada County carried out a major sweep of suspected illegal cannabis grows, destroying thousands of plants and seizing processed cannabis, while an NDPS case in India highlights continued legal scrutiny around cannabis plant parts and packaging. Market/Consumer: New Jersey dispensary Noiré highlights rotating menus and delivery expansion as shoppers look for more guided, education-forward buying.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
